Argolyn Bioscience, Inc. is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Argolyn's most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia.
A second development candidate will soon enter preclinical development as a first-in-class analgesic. These, and other product candidates in our portfolio, were developed using our proprietary amino acid analog substitution technology which enables the rapid and efficient discovery of novel, peptide-based drug candidates.
